The Effect of Amifostine on Acute and Late Radiation Side Effects in Head and Neck Cancer Patients

Details

Serval ID
serval:BIB_7DBE15E9107D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The Effect of Amifostine on Acute and Late Radiation Side Effects in Head and Neck Cancer Patients
Journal
Turkiye Klinikleri Tip Bilimleri Dergisi
Author(s)
Demiroz C., Ozkan L., Cebelli G., Karadag O., Ozsahin E.M.
ISSN
1300-0292
ISSN-L
1300-0292
Publication state
Published
Issued date
2013
Volume
32
Number
5
Pages
1207-1216
Language
english
Abstract
Objective: We aimed to investigate the effect of amifostine on acute and late side effects, and its tolerability in head and neck cancer patients treated with radiotherapy (RT). Material and Methods: The study included 87 patients with primary head and neck cancers and cervical lymph node metastases from unknown primary cancers treated with RT alone or combined with chemotherapy (CT). Forty-one patients (47%) received amifostine combined with RT (ART group) and 46 patients (52%) received RT without amifostine (RT group). The patients were evaluated every week during the treatment and at month 1 and 2 after the completion of RT for acute side effects and month 3, 6, 9, 12, and 24 after the treatment for late side effects according to SOMA/LENT scale. Amifostine was administered prior to RT, along with anti-emetic prophylaxis. The two groups were compared with the Student's t and Mann-Whitney U and Chi-square tests. Results: The ART group had significantly less toxicity (grade! 1 mucositis, grade 2 fibrosis) than patients in the RT group (p=0.001, p=0.03, respectively). At week 3 of RT grade 2 mucositis developed in two patients (5%) in the ART group and 10 patients (22%) in the RT group (p=0.02). The protective effect of amifostine on skin reactions developed at week 4 of RT (p=0.05). Grade 3 xerostomia at 9, 12, and 15 months of follow-up (p=0.02, p=0.02, and p=0.02, respectively), grade 2 xerostomia at 18 and 24 months (p=0.02 and p=0.01, respectively) and fibrosis at 15, 18 and 24 months (p=0.05, p=0.02 and p=0.02, respectively) decreased markedly in the ART group compared with the RT group. Emesis was the most common adverse effect of amifostine. Conclusion: Daily administration of amifostine during RT was effective in avoiding late grade 2-3 xerostomia, as well as grade 2 fibrosis.
Web of science
Open Access
Yes
Create date
23/04/2013 11:24
Last modification date
20/08/2019 14:39
Usage data